You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Access to Exercise Stress Testing for Elderly Native Americans in Remote Locations

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: N

    DESCRIPTION provided by applicant Heart disease is the leading cause of death among elderly American Indians and Alaska Natives Heart disease death rates for elderly American Indians at per are percent higher than average in the total U S population Most elderly Native Americans live in remote locations and lack transportation to healthcare facilities This is a key barrie ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. A cost-effective bioreactor to advance functional tissue engineering of cartilage

    SBC: Apex Biomedical Company, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develop replacement cartilage using tissue engineering (TE) technologies. Although TE cartilage presently lacks the mechanical stability of native cartilage, studies have demonstrated that mechanical stability can be e ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy

    SBC: Neuro Devices, Inc.            Topic: 107

    DESCRIPTION provided by applicant We devised a new generation highly sensitivity method to diagnosis peripheral neuropathy early when the probability for reversal is greatest Cancer chemotherapy and diabetes are the most common causes of neuropathy in the USA Both cause decreased sweating abnormal circulation peripheral numbness pain and weakness If diagnosed early both are potentially ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Administrative Supplement to restore fee funds

    SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.            Topic: NINDS

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. A 3D Printed Resorbable Antimicrobial Envelope to Prevent Infection of Implanted Cardiac Devices

    SBC: N8 MEDICAL INC            Topic: NHLBI

    ABSTRACT Infection is a serious and potentially fatal complication of surgery to deliver cardiovascular implantable electronic devicesCIEDsi epacemakers and implantable cardioverter defibrillatorsUntreated device related infection is associated with mortality rates as high asCurrentlyonly one antibiotic impregnated mesh has been FDA approved for placement in surgical incisions to reduce infections ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma

    SBC: Avenzoar Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Advanced Nitric Oxide Release Bactericidal Urinary Catheters

    SBC: BIOCREDE INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): We propose a novel and competitive urinary tract silicone Foley catheter made from a proprietary polymeric formulation to effectively reduce catheter-associated urinary tract infections (CAUTI) via nitric oxide (NO) release. Preliminary studies show that the device will be able to: (1) continuously deliver NO at rates enough to maintain bactericidal properties ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Advanced Nitric Oxide Release Bactericidal Urinary Catheters

    SBC: BIOCREDE INC.            Topic: 300

    DESCRIPTION provided by applicant In Phase I Biocrede developed a completely new urinary tract silicone Foley catheter with a andgt month shelf life made from a proprietary polymeric formulation to effectively reduce catheter associated urinary tract infections CAUTI via nitric oxide NO release for andgt weeks Key features of the new technology include catheters continuously d ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Advancing clemizole for hepatitis C: towards a pre-IND package

    SBC: EIGER GROUP INTERNATIONAL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government